ID   OXLA_HUMAN              Reviewed;         567 AA.
AC   Q96RQ9; Q1WMJ3; Q4GZN1; Q4GZN2; Q6P2Q3; Q8TEM5; Q96RQ8;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   18-JUN-2025, entry version 184.
DE   RecName: Full=L-amino-acid oxidase {ECO:0000305};
DE            Short=LAAO {ECO:0000305};
DE            Short=LAO {ECO:0000305};
DE            EC=1.4.3.2 {ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:25767141, ECO:0000269|PubMed:26673964, ECO:0000269|PubMed:31812258, ECO:0000269|PubMed:32818467, ECO:0000269|PubMed:32866000};
DE            EC=1.4.3.25 {ECO:0000269|PubMed:26673964};
DE   AltName: Full=Interleukin-4-induced protein 1 {ECO:0000303|PubMed:16029492};
DE            Short=IL4-induced protein 1 {ECO:0000303|PubMed:16029492};
DE            Short=hIL4I1 {ECO:0000303|PubMed:17356132};
DE   AltName: Full=Protein Fig-1 {ECO:0000303|PubMed:12031486};
DE            Short=hFIG1 {ECO:0000303|PubMed:12031486};
DE   Flags: Precursor;
GN   Name=IL4I1 {ECO:0000303|PubMed:16029492};
GN   Synonyms=FIG1 {ECO:0000303|PubMed:12031486};
GN   ORFNames=UNQ636/PRO1265 {ECO:0000303|PubMed:12975309};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   AND INDUCTION.
RX   PubMed=12031486; DOI=10.1016/s0167-4781(02)00295-6;
RA   Chavan S.S., Tian W., Hsueh K., Jawaheer D., Gregersen P.K., Chu C.C.;
RT   "Characterization of the human homolog of the IL-4 induced gene-1 (Fig1).";
RL   Biochim. Biophys. Acta 1576:70-80(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ALTERNATIVE PROMOTER USAGE, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16029492; DOI=10.1186/1741-7007-3-16;
RA   Wiemann S., Kolb-Kokocinski A., Poustka A.;
RT   "Alternative pre-mRNA processing regulates cell-type specific expression of
RT   the IL4l1 and NUP62 genes.";
RL   BMC Biol. 3:16-16(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RA   Chu C.C., Reese S.T., George J., Tian W., Yuan L., Millan C., Marmar J.L.,
RA   Benoff S.;
RT   "Interleukin-4 induced gene-1 variant (IL4I1_v2) is expressed during
RT   spermatogenesis and is decreased in pathologies with hypospermatogenesis.";
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary, and PNS;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 22-36.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=12446450; DOI=10.1182/blood-2002-07-2215;
RA   Copie-Bergman C., Boulland M.L., Dehoulle C., Moeller P., Farcet J.P.,
RA   Dyer M.J., Haioun C., Romeo P.H., Gaulard P., Leroy K.;
RT   "Interleukin 4-induced gene 1 is activated in primary mediastinal large B-
RT   cell lymphoma.";
RL   Blood 101:2756-2761(2003).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, GLYCOSYLATION, TISSUE SPECIFICITY, AND MUTAGENESIS OF GLU-481.
RX   PubMed=17356132; DOI=10.1182/blood-2006-07-036210;
RA   Boulland M.L., Marquet J., Molinier-Frenkel V., Moeller P., Guiter C.,
RA   Lasoudris F., Copie-Bergman C., Baia M., Gaulard P., Leroy K.,
RA   Castellano F.;
RT   "Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature
RT   dendritic cells that inhibits T-lymphocyte proliferation.";
RL   Blood 110:220-227(2007).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-220.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=19436310; DOI=10.1038/leu.2008.380;
RA   Carbonnelle-Puscian A., Copie-Bergman C., Baia M., Martin-Garcia N.,
RA   Allory Y., Haioun C., Cremades A., Abd-Alsamad I., Farcet J.P., Gaulard P.,
RA   Castellano F., Molinier-Frenkel V.;
RT   "The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells
RT   of several B-cell lymphomas and by tumor-associated macrophages.";
RL   Leukemia 23:952-960(2009).
RN   [13]
RP   FUNCTION.
RX   PubMed=23355881; DOI=10.1371/journal.pone.0054589;
RA   Puiffe M.L., Lachaise I., Molinier-Frenkel V., Castellano F.;
RT   "Antibacterial properties of the mammalian L-amino acid oxidase IL4I1.";
RL   PLoS ONE 8:e54589-e54589(2013).
RN   [14]
RP   FUNCTION.
RX   PubMed=25446972; DOI=10.1002/eji.201444897;
RA   Scarlata C.M., Celse C., Pignon P., Ayyoub M., Valmori D.;
RT   "Differential expression of the immunosuppressive enzyme IL4I1 in human
RT   induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.";
RL   Eur. J. Immunol. 45:474-479(2015).
RN   [15]
RP   FUNCTION.
RX   PubMed=25778793; DOI=10.1002/eji.201445000;
RA   Cousin C., Aubatin A., Le Gouvello S., Apetoh L., Castellano F.,
RA   Molinier-Frenkel V.;
RT   "The immunosuppressive enzyme IL4I1 promotes FoxP3(+) regulatory T
RT   lymphocyte differentiation.";
RL   Eur. J. Immunol. 45:1772-1782(2015).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [17]
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=25767141; DOI=10.1530/rep-14-0621;
RA   Houston B., Curry B., Aitken R.J.;
RT   "Human spermatozoa possess an IL4I1 L-amino acid oxidase with a potential
RT   role in sperm function.";
RL   Reproduction 149:587-596(2015).
RN   [18]
RP   FUNCTION, CATALYTIC ACTIVITY, VARIANTS ASP-92 AND GLY-102, AND
RP   CHARACTERIZATION OF VARIANTS ASP-92 AND GLY-102.
RX   PubMed=26673964; DOI=10.1038/gene.2015.55;
RA   Molinier-Frenkel V., Mestivier D., Castellano F.;
RT   "Alterations of the immunosuppressive IL4I1 enzyme activity induced by
RT   naturally occurring SNP/mutations.";
RL   Genes Immun. 17:148-152(2016).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=28891065; DOI=10.1002/eji.201646769;
RA   Aubatin A., Sako N., Decrouy X., Donnadieu E., Molinier-Frenkel V.,
RA   Castellano F.;
RT   "IL4-induced gene 1 is secreted at the immune synapse and modulates TCR
RT   activation independently of its enzymatic activity.";
RL   Eur. J. Immunol. 48:106-119(2018).
RN   [20]
RP   CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=31812258; DOI=10.1016/j.bioorg.2019.103463;
RA   Presset M., Djordjevic D., Dupont A., Le Gall E., Molinier-Frenkel V.,
RA   Castellano F.;
RT   "Identification of inhibitors of the immunosuppressive enzyme IL4I1.";
RL   Bioorg. Chem. 94:103463-103463(2020).
RN   [21]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=32818467; DOI=10.1016/j.cell.2020.07.038;
RA   Sadik A., Somarribas Patterson L.F., Oeztuerk S., Mohapatra S.R.,
RA   Panitz V., Secker P.F., Pfaender P., Loth S., Salem H., Prentzell M.T.,
RA   Berdel B., Iskar M., Faessler E., Reuter F., Kirst I., Kalter V.,
RA   Foerster K.I., Jaeger E., Guevara C.R., Sobeh M., Hielscher T., Poschet G.,
RA   Reinhardt A., Hassel J.C., Zapatka M., Hahn U., von Deimling A., Hopf C.,
RA   Schlichting R., Escher B.I., Burhenne J., Haefeli W.E., Ishaque N.,
RA   Boehme A., Schaeuble S., Thedieck K., Trump S., Seiffert M., Opitz C.A.;
RT   "IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes
RT   tumor progression.";
RL   Cell 182:1252-1270(2020).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=32866000; DOI=10.1021/acs.jafc.0c03735;
RA   Zhang X., Gan M., Li J., Li H., Su M., Tan D., Wang S., Jia M., Zhang L.,
RA   Chen G.;
RT   "An endogenous indole pyruvate pathway for tryptophan metabolism mediated
RT   by IL4I1.";
RL   J. Agric. Food Chem. 68:10678-10684(2020).
CC   -!- FUNCTION: Secreted L-amino-acid oxidase that acts as a key
CC       immunoregulator (PubMed:17356132, PubMed:32818467, PubMed:32866000).
CC       Has preference for L-aromatic amino acids: converts phenylalanine
CC       (Phe), tyrosine (Tyr) and tryptophan (Trp) to phenylpyruvic acid (PP),
CC       hydroxyphenylpyruvic acid (HPP), and indole-3-pyruvic acid (I3P),
CC       respectively (PubMed:17356132, PubMed:32818467, PubMed:32866000). Also
CC       has weak L-arginine oxidase activity (PubMed:26673964). Acts as a
CC       negative regulator of anti-tumor immunity by mediating Trp degradation
CC       via an indole pyruvate pathway that activates the transcription factor
CC       AHR (PubMed:32818467, PubMed:32866000). IL4I1-mediated Trp catabolism
CC       generates I3P, giving rise to indole metabolites (indole-3-acetic acid
CC       (IAA) and indole-3-aldehyde (I3A)) and kynurenic acid, which act as
CC       ligands for AHR, a ligand-activated transcription factor that plays
CC       important roles in immunity and cancer (PubMed:32818467,
CC       PubMed:32866000). AHR activation by indoles following IL4I1-mediated
CC       Trp degradation enhances tumor progression by promoting cancer cell
CC       motility and suppressing adaptive immunity (PubMed:32818467). Also has
CC       an immunoregulatory function in some immune cells, probably by
CC       mediating Trp degradation and promoting downstream AHR activation:
CC       inhibits T-cell activation and proliferation, promotes the
CC       differentiation of naive CD4(+) T-cells into FOXP3(+) regulatory T-
CC       cells (Treg) and regulates the development and function of B-cells
CC       (PubMed:17356132, PubMed:25446972, PubMed:25778793, PubMed:28891065).
CC       Also regulates M2 macrophage polarization by inhibiting T-cell
CC       activation (By similarity). Also has antibacterial properties by
CC       inhibiting growth of Gram negative and Gram positive bacteria through
CC       the production of NH4(+) and H2O2 (PubMed:23355881).
CC       {ECO:0000250|UniProtKB:O09046, ECO:0000269|PubMed:17356132,
CC       ECO:0000269|PubMed:23355881, ECO:0000269|PubMed:25446972,
CC       ECO:0000269|PubMed:25778793, ECO:0000269|PubMed:26673964,
CC       ECO:0000269|PubMed:28891065, ECO:0000269|PubMed:32818467,
CC       ECO:0000269|PubMed:32866000}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an L-alpha-amino acid + O2 + H2O = a 2-oxocarboxylate + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:13781, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:28938, ChEBI:CHEBI:35179,
CC         ChEBI:CHEBI:59869; EC=1.4.3.2; Evidence={ECO:0000269|PubMed:17356132,
CC         ECO:0000269|PubMed:25767141, ECO:0000269|PubMed:26673964,
CC         ECO:0000269|PubMed:32818467, ECO:0000269|PubMed:32866000};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13782;
CC         Evidence={ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:25767141,
CC         ECO:0000269|PubMed:26673964, ECO:0000269|PubMed:32818467,
CC         ECO:0000269|PubMed:32866000};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tryptophan + O2 + H2O = indole-3-pyruvate + H2O2 + NH4(+);
CC         Xref=Rhea:RHEA:61244, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:17640, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:57912; Evidence={ECO:0000269|PubMed:17356132,
CC         ECO:0000269|PubMed:25767141, ECO:0000269|PubMed:32818467,
CC         ECO:0000269|PubMed:32866000};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:61245;
CC         Evidence={ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:25767141,
CC         ECO:0000269|PubMed:32818467, ECO:0000269|PubMed:32866000};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-phenylalanine + O2 + H2O = 3-phenylpyruvate + H2O2 + NH4(+);
CC         Xref=Rhea:RHEA:61240, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:18005, ChEBI:CHEBI:28938,
CC         ChEBI:CHEBI:58095; Evidence={ECO:0000269|PubMed:17356132,
CC         ECO:0000269|PubMed:25767141, ECO:0000269|PubMed:26673964,
CC         ECO:0000269|PubMed:31812258, ECO:0000269|PubMed:32818467};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:61241;
CC         Evidence={ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:25767141,
CC         ECO:0000269|PubMed:26673964, ECO:0000269|PubMed:31812258,
CC         ECO:0000269|PubMed:32818467};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-tyrosine + O2 + H2O = 3-(4-hydroxyphenyl)pyruvate + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:61248, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:28938, ChEBI:CHEBI:36242,
CC         ChEBI:CHEBI:58315; Evidence={ECO:0000269|PubMed:17356132,
CC         ECO:0000269|PubMed:32818467};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:61249;
CC         Evidence={ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:32818467};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-arginine + O2 + H2O = 5-guanidino-2-oxopentanoate + H2O2 +
CC         NH4(+); Xref=Rhea:RHEA:51404, ChEBI:CHEBI:15377, ChEBI:CHEBI:15379,
CC         ChEBI:CHEBI:16240, ChEBI:CHEBI:28938, ChEBI:CHEBI:32682,
CC         ChEBI:CHEBI:58489; EC=1.4.3.25;
CC         Evidence={ECO:0000269|PubMed:26673964};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51405;
CC         Evidence={ECO:0000269|PubMed:26673964};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000250|UniProtKB:O09046};
CC   -!- ACTIVITY REGULATION: L-amino-acid oxidase activity toward phenylalanine
CC       (Phe) is specfically inhibited by a number of Phe derivatives, such as
CC       Cp3 (ethyl 3-(2,6-dichlorophenyl)-2-(piperidin-1-yl)propanoate) or Cp2-
CC       SO4 (PubMed:31812258). Cp3 is a very potent inhibitor for activity
CC       toward phenylalanine but is toxic (PubMed:31812258). In contrast, Cp2-
CC       SO4 is less efficient but not toxic and is able to reverse
CC       immunosuppressive action of IL4I1 in vitro (PubMed:31812258).
CC       {ECO:0000269|PubMed:31812258}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.48 mM for L-phenylalanine {ECO:0000269|PubMed:17356132};
CC   -!- PATHWAY: Amino-acid degradation; L-tryptophan degradation via pyruvate
CC       pathway. {ECO:0000269|PubMed:32818467, ECO:0000269|PubMed:32866000}.
CC   -!- INTERACTION:
CC       Q96RQ9; Q96CV9: OPTN; NbExp=3; IntAct=EBI-20831744, EBI-748974;
CC       Q96RQ9; O76024: WFS1; NbExp=3; IntAct=EBI-20831744, EBI-720609;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:17356132,
CC       ECO:0000269|PubMed:28891065, ECO:0000269|PubMed:32818467}. Lysosome
CC       {ECO:0000250|UniProtKB:O09046}. Cytoplasmic vesicle, secretory vesicle,
CC       acrosome {ECO:0000269|PubMed:25767141}. Note=Secreted at the
CC       immunological synapse. {ECO:0000269|PubMed:28891065}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96RQ9-1; Sequence=Displayed;
CC       Name=2; Synonyms=IL4I1_2 {ECO:0000303|PubMed:16029492};
CC         IsoId=Q96RQ9-2; Sequence=VSP_017173;
CC   -!- TISSUE SPECIFICITY: Primarily found in immune tissues, with the highest
CC       expression in lymph nodes and spleen (PubMed:12031486,
CC       PubMed:12446450). Present in germinal center macrophages and
CC       inflammatory myeloid cells and antigen-presenting cells (at protein
CC       level) (PubMed:17356132). Also present in spermatozoa (at protein
CC       level) (PubMed:25767141). Highly expressed in primary mediastinal large
CC       B-cell lymphoma, a specific subtype of diffuse large B-cell lymphoma
CC       (PubMed:12446450). Expressed by neoplastic cells of several B-cell
CC       lymphomas and by tumor-associated macrophages (PubMed:19436310).
CC       {ECO:0000269|PubMed:12031486, ECO:0000269|PubMed:12446450,
CC       ECO:0000269|PubMed:17356132, ECO:0000269|PubMed:19436310,
CC       ECO:0000269|PubMed:25767141}.
CC   -!- INDUCTION: By IL4/interleukin-4 (PubMed:12031486). Expression is up-
CC       regulated in numerous cancer and metastasis: expression is induced by
CC       immune checkpoint blockade (PubMed:32818467).
CC       {ECO:0000269|PubMed:12031486, ECO:0000269|PubMed:32818467}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:17356132}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Uses the promoter of the upstream NUP62
CC       gene and shares the first 2 non-coding exons with NUP62.
CC       {ECO:0000305|PubMed:16029492}.
CC   -!- SIMILARITY: Belongs to the flavin monoamine oxidase family. FIG1
CC       subfamily. {ECO:0000305}.
CC   -!- CAUTION: According to a report, acts as a negative regulator of T-cell
CC       activation independently of its enzymatic activity (PubMed:28891065).
CC       However, authors of this study only tested enzyme activity via
CC       phenylalanine (Phe) deprivation and not via tryptophan (Trp). As IL4I1
CC       immunoregulator activity is mediated via Trp degradation and subsequent
CC       activation of the transcription factor AHR, additional experiments are
CC       required to confirm this statement (PubMed:32818467, PubMed:32866000).
CC       {ECO:0000269|PubMed:28891065, ECO:0000269|PubMed:32818467,
CC       ECO:0000269|PubMed:32866000, ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB84923.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAI54291.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAI54292.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAI54293.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF293462; AAK73362.1; -; mRNA.
DR   EMBL; AF293463; AAK73363.1; -; Genomic_DNA.
DR   EMBL; AJ880386; CAI54291.1; ALT_INIT; mRNA.
DR   EMBL; AJ880387; CAI54292.1; ALT_INIT; mRNA.
DR   EMBL; AJ880388; CAI54293.1; ALT_INIT; mRNA.
DR   EMBL; DQ079587; AAZ32711.1; -; mRNA.
DR   EMBL; DQ079588; AAZ32712.1; -; mRNA.
DR   EMBL; DQ079589; AAZ32713.1; -; mRNA.
DR   EMBL; AK074097; BAB84923.1; ALT_INIT; mRNA.
DR   EMBL; AY358933; AAQ89292.1; -; mRNA.
DR   EMBL; CH471177; EAW52575.1; -; Genomic_DNA.
DR   EMBL; BC064378; AAH64378.2; -; mRNA.
DR   EMBL; BC090852; AAH90852.2; -; mRNA.
DR   CCDS; CCDS12786.1; -. [Q96RQ9-2]
DR   CCDS; CCDS12787.1; -. [Q96RQ9-1]
DR   RefSeq; NP_001244946.1; NM_001258017.2. [Q96RQ9-2]
DR   RefSeq; NP_001244947.1; NM_001258018.2. [Q96RQ9-2]
DR   RefSeq; NP_690863.1; NM_152899.2. [Q96RQ9-1]
DR   RefSeq; NP_758962.1; NM_172374.3. [Q96RQ9-2]
DR   AlphaFoldDB; Q96RQ9; -.
DR   SMR; Q96RQ9; -.
DR   BioGRID; 129252; 13.
DR   FunCoup; Q96RQ9; 187.
DR   IntAct; Q96RQ9; 5.
DR   STRING; 9606.ENSP00000472474; -.
DR   BindingDB; Q96RQ9; -.
DR   ChEMBL; CHEMBL5291590; -.
DR   DrugBank; DB04166; Anthranilic acid.
DR   DrugBank; DB04272; Citric acid.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB03214; Vinylglycine.
DR   GlyConnect; 1446; 2 N-Linked glycans (2 sites).
DR   GlyCosmos; Q96RQ9; 4 sites, 2 glycans.
DR   GlyGen; Q96RQ9; 5 sites, 16 N-linked glycans (3 sites).
DR   iPTMnet; Q96RQ9; -.
DR   PhosphoSitePlus; Q96RQ9; -.
DR   BioMuta; IL4I1; -.
DR   DMDM; 20138284; -.
DR   jPOST; Q96RQ9; -.
DR   MassIVE; Q96RQ9; -.
DR   PaxDb; 9606-ENSP00000472474; -.
DR   PeptideAtlas; Q96RQ9; -.
DR   ProteomicsDB; 78004; -. [Q96RQ9-1]
DR   ProteomicsDB; 78005; -. [Q96RQ9-2]
DR   Antibodypedia; 32207; 141 antibodies from 25 providers.
DR   DNASU; 259307; -.
DR   Ensembl; ENST00000341114.7; ENSP00000342557.2; ENSG00000104951.16. [Q96RQ9-2]
DR   Ensembl; ENST00000391826.7; ENSP00000375702.1; ENSG00000104951.16. [Q96RQ9-1]
DR   Ensembl; ENST00000595948.5; ENSP00000472474.1; ENSG00000104951.16. [Q96RQ9-2]
DR   GeneID; 259307; -.
DR   KEGG; hsa:259307; -.
DR   MANE-Select; ENST00000391826.7; ENSP00000375702.1; NM_152899.2; NP_690863.1.
DR   UCSC; uc002pqt.2; human. [Q96RQ9-1]
DR   AGR; HGNC:19094; -.
DR   CTD; 259307; -.
DR   DisGeNET; 259307; -.
DR   GeneCards; IL4I1; -.
DR   HGNC; HGNC:19094; IL4I1.
DR   HPA; ENSG00000104951; Group enriched (lymphoid tissue, testis).
DR   MalaCards; IL4I1; -.
DR   MIM; 609742; gene.
DR   OpenTargets; ENSG00000104951; -.
DR   VEuPathDB; HostDB:ENSG00000104951; -.
DR   eggNOG; KOG0029; Eukaryota.
DR   GeneTree; ENSGT00940000162082; -.
DR   HOGENOM; CLU_004498_8_3_1; -.
DR   InParanoid; Q96RQ9; -.
DR   OMA; ADWCVCT; -.
DR   OrthoDB; 5046242at2759; -.
DR   PAN-GO; Q96RQ9; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q96RQ9; -.
DR   PathwayCommons; Q96RQ9; -.
DR   Reactome; R-HSA-8964208; Phenylalanine metabolism.
DR   SignaLink; Q96RQ9; -.
DR   UniPathway; UPA00332; -.
DR   BioGRID-ORCS; 259307; 18 hits in 1156 CRISPR screens.
DR   ChiTaRS; IL4I1; human.
DR   GenomeRNAi; 259307; -.
DR   Pharos; Q96RQ9; Tbio.
DR   PRO; PR:Q96RQ9; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q96RQ9; protein.
DR   Bgee; ENSG00000104951; Expressed in male germ line stem cell (sensu Vertebrata) in testis and 106 other cell types or tissues.
DR   ExpressionAtlas; Q96RQ9; baseline and differential.
DR   GO; GO:0001669; C:acrosomal vesicle; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IDA:UniProtKB.
DR   GO; GO:0001772; C:immunological synapse; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0097225; C:sperm midpiece; IDA:UniProtKB.
DR   GO; GO:0001716; F:L-amino-acid oxidase activity; IDA:UniProtKB.
DR   GO; GO:0106329; F:L-phenylalaine oxidase activity; IEA:RHEA.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0009063; P:amino acid catabolic process; IBA:GO_Central.
DR   GO; GO:0006559; P:L-phenylalanine catabolic process; IDA:UniProtKB.
DR   GO; GO:0006569; P:L-tryptophan catabolic process; IDA:UniProtKB.
DR   GO; GO:0019440; P:L-tryptophan catabolic process to indole-3-acetate; IDA:UniProtKB.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0002841; P:negative regulation of T cell mediated immune response to tumor cell; IDA:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045591; P:positive regulation of regulatory T cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0002819; P:regulation of adaptive immune response; IDA:UniProtKB.
DR   GO; GO:0045577; P:regulation of B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006572; P:tyrosine catabolic process; IDA:UniProtKB.
DR   FunFam; 1.10.405.10:FF:000004; Amine oxidase; 1.
DR   FunFam; 3.50.50.60:FF:000450; Amine oxidase; 1.
DR   FunFam; 3.90.660.10:FF:000011; Amine oxidase; 1.
DR   Gene3D; 3.90.660.10; -; 2.
DR   Gene3D; 3.50.50.60; FAD/NAD(P)-binding domain; 1.
DR   Gene3D; 1.10.405.10; Guanine Nucleotide Dissociation Inhibitor, domain 1; 1.
DR   InterPro; IPR002937; Amino_oxidase.
DR   InterPro; IPR036188; FAD/NAD-bd_sf.
DR   InterPro; IPR001613; Flavin_amine_oxidase.
DR   InterPro; IPR050281; Flavin_monoamine_oxidase.
DR   PANTHER; PTHR10742; FLAVIN MONOAMINE OXIDASE; 1.
DR   PANTHER; PTHR10742:SF21; L-AMINO-ACID OXIDASE; 1.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   PRINTS; PR00757; AMINEOXDASEF.
DR   SUPFAM; SSF54373; FAD-linked reductases, C-terminal domain; 1.
DR   SUPFAM; SSF51905; FAD/NAD(P)-binding domain; 1.
DR   neXtProt; NX_Q96RQ9; -.
DR   PharmGKB; PA38795; -.
DR   TreeFam; TF313314; -.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Alternative promoter usage; Alternative splicing;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disulfide bond; FAD;
KW   Flavoprotein; Glycoprotein; Immunity; Lysosome; Oxidoreductase;
KW   Proteomics identification; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           22..567
FT                   /note="L-amino-acid oxidase"
FT                   /id="PRO_0000001710"
FT   REGION          506..567
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        553..567
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         69..70
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         89..90
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         97
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         113..116
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         116
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         287
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         398
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         481
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000305|PubMed:17356132"
FT   BINDING         488..493
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   BINDING         488..489
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        134
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        220
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        559
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..199
FT                   /evidence="ECO:0000250|UniProtKB:P81382"
FT   VAR_SEQ         1..5
FT                   /note="MAPLA -> MPNDDFCPGLTIKAMGAERAPQRQPCT (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16029492, ECO:0000303|Ref.3"
FT                   /id="VSP_017173"
FT   VARIANT         92
FT                   /note="N -> D (increased L-amino-acid oxidase activity;
FT                   dbSNP:rs111772144)"
FT                   /evidence="ECO:0000269|PubMed:26673964"
FT                   /id="VAR_083941"
FT   VARIANT         102
FT                   /note="R -> G (in an ovarian cancer; decreased L-amino-acid
FT                   oxidase activity)"
FT                   /evidence="ECO:0000269|PubMed:26673964"
FT                   /id="VAR_083942"
FT   VARIANT         501
FT                   /note="A -> S (in dbSNP:rs2290772)"
FT                   /id="VAR_048260"
FT   MUTAGEN         481
FT                   /note="E->A: Abolished L-amino-acid oxidase activity."
FT                   /evidence="ECO:0000269|PubMed:17356132"
FT   CONFLICT        24
FT                   /note="W -> R (in Ref. 7; AAH64378)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        114
FT                   /note="A -> T (in Ref. 2; CAI54291/CAI54293)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   567 AA;  62881 MW;  FFF953CB28D22F19 CRC64;
     MAPLALHLLV LVPILLSLVA SQDWKAERSQ DPFEKCMQDP DYEQLLKVVT WGLNRTLKPQ
     RVIVVGAGVA GLVAAKVLSD AGHKVTILEA DNRIGGRIFT YRDQNTGWIG ELGAMRMPSS
     HRILHKLCQG LGLNLTKFTQ YDKNTWTEVH EVKLRNYVVE KVPEKLGYAL RPQEKGHSPE
     DIYQMALNQA LKDLKALGCR KAMKKFERHT LLEYLLGEGN LSRPAVQLLG DVMSEDGFFY
     LSFAEALRAH SCLSDRLQYS RIVGGWDLLP RALLSSLSGL VLLNAPVVAM TQGPHDVHVQ
     IETSPPARNL KVLKADVVLL TASGPAVKRI TFSPPLPRHM QEALRRLHYV PATKVFLSFR
     RPFWREEHIE GGHSNTDRPS RMIFYPPPRE GALLLASYTW SDAAAAFAGL SREEALRLAL
     DDVAALHGPV VRQLWDGTGV VKRWAEDQHS QGGFVVQPPA LWQTEKDDWT VPYGRIYFAG
     EHTAYPHGWV ETAVKSALRA AIKINSRKGP ASDTASPEGH ASDMEGQGHV HGVASSPSHD
     LAKEEGSHPP VQGQLSLQNT THTRTSH
//
